References
- Early Breast Cancer Trialists' Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
- Partridge AH, Gelber S, Peppercorn J, Sampson E, Knundsen K, Laufer M, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 2004; 22: 4174–4183.
- Walshe JM, Denduluri N, Swain SM. Amenorrhea in pre-menopausal women after adjuvant chemotherapy for breast can-cer. J Clin Oncol 2006; 24: 5769–5779.
- Petrek JA, Naughton MJ, Case LD, Paskett ED, Naftalis EZ, Singletary SE, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospec-tive study. J Clin Oncol 2006; 24: 1045–1051.
- Del Mastro L, Venturini M, Sertoli MR, Rosso R. Amen-orrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implication. Breast Cancer Res Treat 1997; 43: 183–190.
- Fox KR, Scialla J, Moore M. Preventing chemotherapy-related amenorrhea using leuprolide during adjuvant chemother-apy for early-stage breast cancer. Proc Am Soc Clin Oncol 2003; 22:13.
- Recchia F, Saggio G, Amiconi G, Di Blasio A, Cesta A, Candeloro G, et al. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast car-cinoma. Cancer 2006; 106: 514–523.
- Del Mastro L, Catzeddu T, Boni L, Bell C, Sertoli MR, Bi-ghin C, et al. Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Ann Oncol 2006; 17: 74–78.
- Urruticoechea A, Walsh G, Rigg A, Dowsett M, Smith LE. Ovarian function protection with goserelin during adjuvant chemotherapy in premenopausal women with early breast can-cer. Breast Cancer Res Treat 2004; 88 (Suppl 1): S 229.
- French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year fol-low-up results of French Adjuvant Study Group 05 Randomized Trial. J Clin Oncol 2001; 19: 602–611.
- Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006; 24: 2917–2931.
- Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreat-ment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist 2007; 12: 1044–1054.
- Abusief ME, Missmer SA, Ginsburg ES, Weeks JC, Winer EP, Partridge AH. Chemotherapy-related amenorrhea in women with early breast cancer: The effect of paclitaxel or dose density. Proc Am Soc Clin Oncol 2006; 24:10506.
- Moore HCF, Theriault RL. Commentary: Ovarian func-tion does not equal fertility does not equal babies. Oncologist 2007; 12: 1067–1069.
- Lobo RA. Potential options for preservation of fertility in women. N Engl J Med 2005; 353: 64–73.